About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Contact the Docs


  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat #8 Overall Rank


« Azurity Pharmaceuticals Inc. v. Alkem Laboratories Ltd. (Fed. Cir. 2023) | Main | Judge Newman Suspended for One Year by Federal Circuit »

September 19, 2023


Thank you for this post. In view of this and many other public comments blaming pharma companies for high drug prices, I was surprised to recently learn more about how PBMs (Pharmacy Benefit Managers) can distort pricing on biologicals. The article linked below focuses on Humira biosimilars, noting that prices may not come down much even when so many biosimilars are poised to enter the market. I still don't quite understand exactly how or why this pricing scheme originated, but it seems to be another feature of US health care that really works against patients getting reasonably priced treatments. It would be great to see more scrutiny of issues like this versus just demonizing the drug companies that invest in bringing medicines to market.


The comments to this entry are closed.

May 2024

Sun Mon Tue Wed Thu Fri Sat
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31